Get the app
US › Healthcare

Innoviva Inc (INVA)

US · Healthcare · Biotechnology

$19.10-0.73%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue
$106.1M
Revenue YoY
-1.6%
Net profit
$-73.9M
Profit YoY
-182.2%
EPS
$0.50
EPS estimate
$0.49
Net margin
-69.6%

EPS came in at 0.50 against a street estimate of 0.49 — a beat of 2.0%.

Key statistics

Market cap
$1.54B
P/E
5.0
Forward P/E
9.4
P/B
1.23
Book value
$16.98
EPS (TTM)
$4.28
52-week high
$25.15
52-week low
$19.00
50-day MA
$20.99
200-day MA
$21.90
Beta
0.37

Analyst view

Analysts rate Innoviva Inc a buy (4 buy, 0 hold, 1 sell out of 5) with an average price target of $35.00.

Shareholding

Insiders
1.01%
Institutions
109.02%

Largest institutional holders

FundStake
BlackRock Inc15.99%
Dimensional Fund Advisors, Inc.6.22%
Vanguard Portfolio Management, LLC5.84%
Renaissance Technologies Corp5.59%
State Street Corp4.52%
Vanguard Capital Management, LLC4.37%
Millennium Management LLC3.52%
Geode Capital Management, LLC2.87%

Recent filings & reports

DocumentDate
Quarterly report · Q3 2026
HEADLINE NUMBERS • Third-quarter 2026 revenue was $106,120 thousand, compared with $107,800 thousand in the third quarter of 2025. • Nine-month 2026
2026-11-04
Results announced · Q4 2026
HEADLINE NUMBERS • Q3 2026 total revenue was $106.1 million, down 1.6% from $107.8 million in Q3 2025. • Net product sales were $49.4 million, inclu
2026-11-04
Quarterly report · Q2 2026
INNOVIVA, INC. – 10-Q SUMMARY (JUNE 30, 2026) HEADLINE NUMBERS • Total Revenue (6 months): $217.6 million vs. $188.9 million prior year (+15.2%) -
2026-08-05
Results announced · Q3 2026
INNOVIVA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total revenue: $119.6 million, up 19% year-over-year from $100.3 million in Q2 2025 •
2026-08-05
Board / officer change · Q2 2026
INNOVIVA, INC. – 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Two board members resigned on May 12, 2026: Derek Small (CEO of Syndeio BioSciences Inc
2026-05-18
Quarterly report · Q1 2026
INNOVIVA, INC. — 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Q1 2026 Net Income: $186.6 million (vs. Q1 2025 net loss of $46.6 million) • Q1 2026 Net
2026-05-06
Results announced · Q2 2026
INNOVIVA, INC. – Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total revenue: $98.0 million, up 11% from $88.6 million in Q1 2025 • Royalty revenue (
2026-05-06
Shareholder vote results · Q2 2026
INNOVIVA, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 4, 2026 • Total shares voted: approximately 66 million (56.7m fo
2026-05-04

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Innoviva Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-11-07.